Hello. My mother in law was diagnosed with NSC lung cancer in 9/2012 aged 62, non smoker excellent health. T2, N1,MO, 1/3 lymph nodes positive, left lower lobectomy and three months of adjunctive chemo.
She then had no treatment until spinal mets appeared in Nov 2013 and her orignal lung sample was tested and EGFR mutation detected. She immediately began treatment with Afantinib and her response was described as "brilliant".
12/2014 spinal met to t9 treated very successfully with radiation and Afantinib continued.
May 2015 Cancer markers rising but no scans ordered. July 2015 new spinal lesion and no improvement in two existing lesions , mother in law complaining of side effects of Afantinib (sore toes) and when Oncologist stated she had become resistant to Afantinib and suggested she stop taking it she agreed.
August 2015 rejected for ADZ 9291 as disease was considered as "not progressed" but was able to join Nivolumab trial.
Sept 2015 right side hemisensory loss, MRI shows three lesions to brain, whole brain radiation suggested. Family questioned benefits of Gamma Knife, not available in Perth (Western Australia) but available in one hospital in Sydney. Strongly advised against this "risky procedure" however travelled to Sydney to get second opinion (Onco and Rad) and fine cut MRI found 5 mets and these were treated.
(Now) 3 months later still hemisensory loss, she says it improves and then worsens after Nivolumab.
Last week 800ml malignant pleural effusion, returned one week. Today pleurodesis undertaken (plus 1ltr fluid but not 100% successful as no lower left lung to adhere to pleura.
Last dose of Nivolumab due this week. Makers have come down from high of 50 to 30 now.
My question (finally): is there still a place for Afantinib in the treatment of what is now described by her medical team as late stage lung cancer? AZD9291 not available in a Australia except trials and no tumours to biopsy.